CS0159 NASH Indications IND, a new class I drug of Cascade, was approved in the United States

Recently, Cascade announced that the new FXR agonist CS0159, jointly developed by Eric Xu, the founder of the company, and Li Jia, the team of the Shanghai Institute of Pharmacy, has obtained the implied permission of the US Food and Drug Administrat